skip to Main Content

April 3, 2020
Fair Pricing for Cepheid Xpert Tests (COVID-19, HIV, TB, HCV)
Webinar / Presentation
On Friday, April 3, Treatment Action Group (TAG) and Médecins Sans Frontières (MSF), and the Global Coalition of TB Activists (GCTA) held a webinar on the price of Xpert tests for COVID-19, TB, HIV, HCV and other diseases.

March 31, 2020
TAG Statement on WHO Updated TB Preventive Therapy Guidance
Statement / Press
Last week, Treatment Action Group was pleased to receive the World Health Organization’s (WHO) update to its guidance on TB preventive therapy (TPT).

March 27, 2020
Treatment Action Group Statement on the High Price of Cepheid’s Xpert Test for COVID-19
Statement / Press
Cepheid is profiteering during a pandemic, with dangerous consequences for countries with vulnerable populations and health systems. New York, March 27, 2020 — Treatment Action Group calls for Cepheid to immediately lower to US$ 5 the developing country price of its rapid, cartridge-based test for detecting SARS-CoV-2, the virus that…

March 25, 2020
Science-Based Activism to End Epidemics, from AIDS to COVID-19
Statement / Press
We hope you’re staying safe and sanitized during this difficult time! Here at TAG, we’re fortunate to be able to safely work from home, and advance the fight against HIV, tuberculosis, and hepatitis C — and now against COVID-19.

March 20, 2020
Public Comment for Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products
Letter / Comment
TAG submitted comments in response to FDA Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products. Further guidance for research on treatments for rare diseases is needed, but stringent regulatory authority and quality clinical trial design must not be sacrificed in the name of expediency.

March 16, 2020
CROI 2020 TB Round Up
Statement / Press
Treatment Action Group welcomes the flurry of tuberculosis (TB) data reported at the 2020 Conference on Retroviruses and Opportunistic Infections (CROI). This statement includes a summary of major findings, TAG’s take on them, and a more detailed overview of key findings.

March 9, 2020
Leading Community Activists and Epidemiologists Demand NYC Take Stronger Action to Mitigate COVID-19 Outbreak
Letter / Comment
TAG, PrEP4ALL and a number of other organizations/individuals sent this letter to New York City Mayor Bill DeBlasio, Council Speaker Corey Johnson, and Health Commissioner Oxiris Barbot. It demands immediate transparency on, and public involvement in, their response to the COVID-19 outbreak, and requests a conversation with the staff of…

March 3, 2020
Isoniazid/Rifapentine (3HP) Access Roadmap and Patent Landscape
Publication
Our publication, Isoniazid/Rifapentine (3HP) Access Roadmap and Patent Landscape, provides a landscape of patent applications filed by the French pharmaceutical company Sanofi on combinations of two essential medicines used to prevent tuberculosis (TB): isoniazid and rifapentine.

February 14, 2020
An Activist’s Guide to the LAM Test
Publication
Tuberculosis (TB) is the number one killer of people living with HIV/AIDS, causing one in three of all AIDS-related deaths. People living with HIV are at increased risk of developing TB, and of dying from it—especially when they have advanced HIV disease, or AIDS. The LAM test can rapidly and…

January 24, 2020
TAG Comment on the Trans-NIH Strategic Plan Goals for Sexual & Gender Minority (SGM) Health Research
Letter / Comment
TAG submitted this public comment in response to a Request for Information on the Development of the Fiscal Year 2021-2025 Trans-NIH Strategic Plan for Sexual & Gender Minority Health Research, affirming the need for a research agenda that will best address HIV, TB, and HCV among LGBTQ+ communities and incorporate…

Back To Top